Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • TOP STORY—Iowa Sup. Ct.: Alleged price fixing conspiracy more akin to “traditional health insurance”
    • ACQUISITIONS & MERGERS NEWS: FTC seeks comments on consent agreement on Novartis-GlaxoSmithKline acquisition
    • ADVERTISING NEWS: FTC halts auto shipment broker’s promotion of “unbiased” consumer reviews
    • ADVERTISING—N.D. Cal.: “No Sugar Added” claim truthful, despite use of concentrated fruit juice
    • ANTITRUST NEWS: Foam manufacturers denied High Court review in price fixing class action
    • ANTITRUST—E.D. Mich.: Auto parts supplier escapes price fixing claims, manufacturers not so lucky
    • ANTITRUST—N.D. Ohio: Settlements approved in polyurethane foam class action
    • CONSUMER PROTECTION NEWS: FTC settles action alleging product scam targeting Spanish-speaking consumers
    • CONSUMER PROTECTION NEWS: Identity theft, imposter scams top FTC consumer complaints
    • CONSUMER PROTECTION—N.D. Cal.: FTC, AT&T to address how FCC Order will affect litigation
    • LAW FIRM NEWS: Antitrust litigator Mark M. Elliott joins Phillips Nizer
    • STATE UNFAIR TRADE PRACTICES—C.D. Cal.: Customer not bound by arbitration agreement buried on marketer’s website
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Antitrust Law Daily Wrap Up, ACQUISITIONS & MERGERS NEWS: FTC seeks comments on consent agreement on Novartis-GlaxoSmithKline acquisition, (Mar 2, 2015)

    Organizations Mentioned:GlaxoSmithKline PLC | GlaxoSmithKline, PLC | Novartis AG

    By Edward L. Puzzo, J.D.

    The FTC has published for comment the terms of its proposed consent agreement with pharmaceutical company Novartis AG, designed to remedy the anticompetitive effects of Novartis’ proposed acquisition of oncology assets from GlaxoSmithKline PLC ...

    By Edward L. Puzzo, J.D.

    The FTC has published for comment the terms of its proposed consent agreement with pharmaceutical company Novartis AG, designed to remedy the anticompetitive effects of Novartis’ proposed acquisition of oncology assets from GlaxoSmithKline PLC (80 Fed. Reg. 11202, March 2, 2015).

    This follows the FTC’s recent announcement that Switzerland-based Novartis has agreed to divest all assets related to its BRAF and MEK protein-coding gene inhibitor drugs currently in development, to Colorado-based Array BioPharma, in order to settle FTC charges that Novaris’ $16 billion acquisition of UK-based pharmaceutical company GlaxoSmithKline’s portfolio of cancer treatment drugs would likely be anticompetitive.

    Comments on the consent agreement must be received on or before March 25, 2013. Interested parties may file a comment here or mail a comment to: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC–5610 (Annex D), Washington, DC 20580.

    Companies: Novartis AG; GlaxoSmithKline PLC

    News: AcquisitionsMergers Antitrust FederalTradeCommissionNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use